WE PHARMA, INC.

WE PHARMA, INC. specializes in the manufacturing and distribution of pharmaceutical drug products for federal research and regulatory support missions. The company’s core capabilities center on the production of physicochemical and formulated drug substances, with deep expertise in GMP-compliant manufacturing processes for FDA research programs. They supply reliably sourced, market-available pharmaceuticals to support scientific studies under the GDUFA Regulatory Science Program, ensuring compliance with stringent quality control standards for analytical and preclinical applications. Their technical proficiency spans active pharmaceutical ingredient (API) processing, formulation development, and end-to-end product validation, positioning them as a trusted source for mission-critical drug materials used in government-led research initiatives. The contractor maintains a consistent and exclusive relationship with the Department of Health and Human Services, delivering both manufactured pharmaceuticals and wholesale distribution services under task orders and IDIQ vehicles. Their work directly supports the FDA’s Office of Testing Research, providing essential drug products for regulatory science studies, indicating a high-trust, mission-aligned partnership focused on sustaining the agency’s scientific infrastructure. Industry focus is narrowly concentrated in pharmaceutical preparation manufacturing (NAICS 325412), with supplementary activity in drug wholesaling (NAICS 424210). This dual focus reflects a vertically integrated model that bridges production and supply chain logistics, serving federal agencies requiring secure, compliant access to both finished dosage forms and bulk pharmaceutical materials. The company’s market positioning is defined by its ability to deliver regulated drug products at scale for public health research applications. As a small business entity structured as 2L and headquartered in Morrisville, NC, WE PHARMA, INC. operates without federal certifications but maintains a focused presence in the government pharmaceutical supply market, emphasizing reliability and regulatory alignment over scale or broad certification portfolios.